Goldman Sachs Group Inc Heron Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,707,152 shares of HRTX stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,707,152
Previous 1,415,069
20.64%
Holding current value
$1.83 Million
Previous $4.95 Million
31.4%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding HRTX
# of Institutions
180Shares Held
121MCall Options Held
80.4KPut Options Held
94.9K-
Rubric Capital Management LP New York, NY26.7MShares$28.6 Million1.48% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.85MShares$9.47 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.72MShares$9.33 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$8.91 Million0.0% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$7.48 Million28.8% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $127M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...